Drugging Autophagy Summit

Drugging Autophagy Summit

November 19-20 2020 | EDT Timezone

Deciphering the Druggability of Autophagy-Driven Diseases

 

Re-engineered for Online

Find Out More Agenda

The Drugging Autophagy Summit Goes Online for 2020

With more targets for Autophagy-Driven diseases being unlocked with every passing day, the need to meet and learn together is greater than ever before. As an industry, we cannot afford to put things on hold.

The Drugging Autophagy Summit has been completely re-engineered to deliver the best learning experience together with exciting new networking opportunities.

The Drugging Autophagy Summit Goes Online for 2020
Key Features
Interactive Learning

The agenda is purposely built to provide an engaging and interactive learning experience.  integrated polls, Q&A with speakers, roundtable discussions, and more, you will be able to accelerate your knowledge of “undruggable” R&D as it explodes into the mainstream. The ability to actively or passively be involved in these learning opportunities is yours!

Dynamic Networking

Replicate those all-important ‘water cooler’ moments through randomly assigned networking or join discussion-led sessions to find those with similar interests to you. Scroll through the entire attendee list to message your fellow attendees, schedule 1-2-1 video calls, or create your own private session rooms for group discussions. The Drugging Autophagy Summit will enable you to meet more senior R&D and business exec’s from across the industry, all from the comfort of your own home!

Meeting Point DTx East
Personalized Participation

The Digital Platform lets you create your own personal agenda. You can attend live sessions, watch on-demand content, take part in open networking sessions, or take a break whenever suits you. Seamlessly hop between learning and networking at any time. Look through the program and slot sessions directly into your calendar, to help fit the conference around the day job.

The Drugging Autophagy Summit, brings together industry and academics in a unique format. It is a perfect place to share findings across disciplines, and accelerate the pace of drug discovery in the autophagy field.

Ravi Amaravadi, University of Pennsylvania | Pinpoint Therapeutics

The Drugging Autophagy Summit will bring together scientists and physicians in the public and private sector to discuss how best to target autophagy and in what disease indications.

Martin McMahon, University of Utah

Rapid advances in our understanding of autophagy provide a tremendous opportunity to take the field to the next level by developing novel strategies to deliberately manipulate autophagy to treat or prevent disease. By discussing the pros and cons of these approaches, this Summit will provide a great space to push these ideas forward.

Andrew Thorburn, University of Colorado

Expert Speaker Faculty

Alec Kimmelman
Alec Kimmelman
Professor & Chair of the Department of Radiation Oncology | Founder & Scientific Consultant
NYU Langone Medical Center | Vescor Therapeutics
Alec Kimmelman
Professor & Chair of the Department of Radiation Oncology | Founder & Scientific Consultant
NYU Langone Medical Center | Vescor Therapeutics

Alec Kimmelman, M.D., Ph.D. is Professor and Chair of the Department of Radiation Oncology at NYU Langone Medical Center and a member of the Perlmutter Cancer Center at NYU. His laboratory has made seminal contributions to our understanding of pancreatic cancer – the fourth leading cause of cancer death in the US. In particular, recent work from his lab has established that pancreatic tumors rely on autophagy (“self-eating”) for proper growth. His research has elucidated unique metabolic pathways in pancreatic cancer and has identified how the Kras oncogene can re-wire the metabolism of these tumors.This body of work has served to define the metabolic landscape of pancreatic cancer and has paved the way for multiple clinical trials in this disease. 

 

His own research has been published in many prestigious journals, including Cell, Science, Nature, Cancer Cell, Cancer Discovery, and Genes & Development. He has received numerous honors and awards, including the Ruth Leff Siegel Award for Excellence in Pancreatic Cancer Research from Columbia University for the researcher who has made the most significant contribution to pancreatic cancer research and he was elected to the American Society of Clinical Investigation.

Magdalene Moran
Magdalene Moran
President & CSO
Caraway Therapeutics
Magdalene Moran
President & CSO
Caraway Therapeutics

Magdalene Moran, PhD, is a leading researcher in drug discovery with particular expertise in novel ion channels.  Prior to joining Caraway Therapeutics, Dr. Moran spent over 15 years at Hydra Biosciences, where she was SVP of Biology. She has PhD in Neurobiology from Harvard University (Lab of David Clapham) and a BA in biology with a concentration in neuroscience from Williams College.

Ravi Amaravadi
Ravi Amaravadi
Associate Professor of Medicine | Co-Leader
University of Pennsylvania | Cancer Therapeutics Program Abramson Cancer Center
Ravi Amaravadi
Associate Professor of Medicine | Co-Leader
University of Pennsylvania | Cancer Therapeutics Program Abramson Cancer Center

Dr. Amaravadi completed training at Columbia University, Johns Hopkins University, the Brigham and Women’s Hospital, and University of Pennsylvania. He was one of the first to demonstrate that targeting autophagy can augment cancer therapy in animal models. He has translated this finding into nearly a dozen clinical trials testing hydroxychloroquine (HCQ) as a possible anticancer agent in multiple cancers.  With Dr. Jeffrey Winkler at UPENN he has developed a series of next generation chloroquine derivatives, and identified their molecular target. He is an Associate Editor for the journal Autophagy, and has been the lead organizer for the first two Autophagy and Cancer Banbury meetings in 2016 and 2018.  He is co-Founder of Pinpoint Therapeutics and serves as an advisor to multiple drug development programs.

Daniel Flynn
Daniel Flynn
Founder & CSO
Deciphera Pharmaceuticals
Daniel Flynn
Founder & CSO
Deciphera Pharmaceuticals

Daniel L. Flynn, PhD is Founder and Chief Scientific Officer of Deciphera Pharmaceuticals, a company he founded in 2003. His present research passion at Deciphera is in the area of small molecule kinase modulation through control of kinase conformational shape.  This platform, called switch control inhibition, has been utilized at Deciphera to produce multiple drugs, 3 of which are currently in clinical development. Deciphera’s research in oncology has focused on tumor driver mutations, cancer cell metabolism, cancer immunotherapy, and the tumor microenvironment.   Deciphera’s clinical stage drug pipeline includes DCC-2618, rebastinib, and DCC-3014. The ULK inhibitor DCC-3116 is currently in IND-enabling development. 

Dan received a B.S. in Pharmacy from the University of Kansas in 1977, and then stayed at KU to receive his PhD in medicinal chemistry in 1981. After completing a post-doctorate in synthetic organic chemistry at Indiana University, he joined Warner-Lambert/Parke Davis Pharmaceuticals in Ann Arbor, Michigan, in 1983. From 1988 to 2002, Dan held positions in Searle Pharmaceuticals in Skokie, IL and later St. Louis, MO, Amgen, Inc in Thousand Oaks, CA, and Millennium Pharmaceuticals in Cambridge, MA.  Dan is an Adjunct Professor of Medicinal Chemistry at the University of Kansas-Lawrence and has served as the National Chair for the Division of Medicinal Chemistry of the American Chemical Society. Dan was inducted as an American Chemical Society Fellow in 2013. Dan has authored or co-authored over 100 publications in peer-reviewed journals and has been named an inventor on over 70 patents during his career.

Peter Hamley
Peter Hamley
CSO
Samsara Therapeutics
Peter Hamley
CSO
Samsara Therapeutics

Peter is a recognized industry leader in drug discovery, having spent 15 years at Sanofi, most recently as Global Head of External Innovation, Drug Discovery. Prior to his business development role, he led global medicinal and automated chemistry, natural product and antibody drug conjugate departments across Germany, France, and the US, with divisions of more than 100 international FTEs, and has contributed to the advancement of many projects into clinical development across multiple therapeutic areas. He started his career at AstraZeneca with a decade of leading medicinal chemistry teams in the respiratory and inflammation disease areas. His academic career spans postdoctoral positions with Prof Amos B. Smith III and Prof Ralph Hirschmann at the University of Pennsylvania, a PhD from the University of Cambridge, and a BSc in Chemistry from Imperial College London (first class honours). He holds an MBA from the University of Bath. Over his career in big pharma, he has been involved in hundreds of drug discovery projects. He executed Sanofi’s Lab031 partnership with Evotec, Sanofi’s natural product partnership with the Fraunhofer Institute, been part of the negotiating teams for the divestment of the Toulouse and Tucson Sanofi sites, and pioneered Sanofi’s risk-sharing approach to early drug discovery with academics and commercial partners, and he set up Sanofi’s partnerships in artificial intelligence for drug discovery. He has published numerous papers and patents and was co-editor of the textbook Small Molecule Medicinal Chemistry: Strategies and Technologies (Wiley).

Jens Eckstein
Jens Eckstein
Interim CEO, President & Director
Samsara Therapeutics
Jens Eckstein
Interim CEO, President & Director
Samsara Therapeutics

Jens has more than 15 years of venture capital experience in biopharma and 10 years of operational experience in drug discovery and development. Jens is a Kauffman Fellow and a mentor for life science entrepreneurs and start-up teams in the area of innovative life science and healthcare IT companies.  

Before joining Apollo Ventures, Jens served as President of SR One for eight years. He is also co-founder and Managing Director of Action Potential Venture Capital (APVC). Previously, Jens was a General Partner at TVM Capital leading early-stage investments in Boston and was CEO and President of SelectX Pharmaceuticals. Before his investment career, Jens was leading research teams and pharma collaborations at Enanta Pharmaceuticals (NASDAQ: ENTA) and Mitotix.

Martin McMahon
Martin McMahon
Cumming-Presidential Chair of Cancer Biology/Senior Director for Preclinical Translation
University of Utah
Martin McMahon
Cumming-Presidential Chair of Cancer Biology/Senior Director for Preclinical Translation
University of Utah

Dr. Martin McMahon currently serves as the Cumming-Presidential Chair of Cancer Biology in the Dept. of Dermatology at the University of Utah, Senior Director for Preclinical Translation and Co-Leader of the Experimental Therapeutics Program in the Huntsman Cancer Institute.

Dr. McMahon’s translational cancer research program focuses on the mechanisms underlying the initiation, progression and maintenance of metastatic melanoma, lung and pancreatic cancer.  Although these malignancies are derived from distinctly different cell types, they share a striking number of common genetic alterations, especially mutations in the KRAS, BRAF or PIK3CA proto-oncogenes.  To do this, Dr. McMahon’s laboratory uses genetically engineered mouse models, patient-derived xenografts and cultured cancer-derived cell lines.

Andrew Thorburn
Andrew Thorburn
Professor & Chair, Department of Pharmacology
University of Colorado.
Andrew Thorburn
Professor & Chair, Department of Pharmacology
University of Colorado.

Andrew Thorburn trained at the Universities of Glasgow, Oxford and University of California San Diego. He is currently at the University of Colorado where he is Professor and Chair of the Department of Pharmacology. Dr. Thorburn is an author of more than 150 scientific publications and has held multiple research grants from NIH and other agencies. The Thorburn lab studies autophagy’s roles in cell death and cancer therapy.

Sean Smith
Sean Smith
Executive Director of Neuroscience Discovery
Merck
Sean Smith
Executive Director of Neuroscience Discovery
Merck

Sean M. Smith, Ph.D. is an Executive Director of Neuroscience Discovery at Merck in West Point, PA.  In this role, he directs research for Neurodegenerative disease from target identification to early clinical development.  He also leads efforts to identify and translate target engagement and disease progression biomarkers for neurological disorders.  Prior to leading the Neurodegeneration department, Sean lead the Psychiatric Disorders department and was the chair of early clinical development teams for MK-8189 (Phase 2, schizophrenia) and MK-8719 (Phase 1, PSP).  Sean did his postdoctoral training at the Salk Institute for Biological Studies in the laboratory of Dr Wylie Vale and received his Ph.D. in Neuroscience from the University of Illinois at Urbana-Champaign.

Evripids Gavathiotis
Evripids Gavathiotis
Professor of Biochemistry and Medicine | Co-founder
Albert Einstein College of Medicine | Selphagy Therapeutics
Evripids Gavathiotis
Professor of Biochemistry and Medicine | Co-founder
Albert Einstein College of Medicine | Selphagy Therapeutics

Dr. Evris Gavathiotis is a Professor of Biochemistry and Medicine at Albert Einstein College of Medicine and faculty member of the Albert Einstein Cancer Center and the Institute for Aging Research among others. His research focuses on mechanisms and protein interactions in cell death and cell survival signaling and the discovery and optimization of small molecule modulators towards novel chemical tools and therapeutics.

Fiona Menzies
Fiona Menzies
Research Advisor & Head of Proteostasis
Eli Lilly
Fiona Menzies
Research Advisor & Head of Proteostasis
Eli Lilly

Fiona currently leads an Alzheimer’s Disease drug discovery team working on targets in protein degradation and homeostasis with a focus on tau biology. Her career has been dedicated to understanding the underlying mechanisms of neurodegeneration. Prior to joining Lilly she worked at University of Cambridge in the lab of Prof. David Rubinsztein studying the potential for autophagy modulation as a therapeutic target for neurodegenerative as well as the contribution of autophagy perturbation to the underlying pathogenesis in neurodegenerative diseases.

Aditya Murthy
Aditya Murthy
Senior Scientist
Genentech
Aditya Murthy
Senior Scientist
Genentech

The Murthy lab’s research interests span innate immunity, human genetics and protein homeostasis. Given its emergent relevance to human disease, investigating the mechanisms by which autophagy controls inflammation is a major focus area. The Murthy lab utilizes functional genomics and proteomics to reveal therapeutically relevant immuno-modulatory pathways regulated by autophagy.

John Skidmore
John Skidmore
CSO
Alzheimer’s Research UK Cambridge Drug Discovery Institute
John Skidmore
CSO
Alzheimer’s Research UK Cambridge Drug Discovery Institute

John Skidmore is a chemist by training, receiving a BA and DPhil from the University of Oxford. Following a post doc at the University of Liverpool with Prof Stan Roberts, John joined GSK where he worked as a medicinal chemist and project leader in the pain and neurodegeneration therapeutic areas. In 2010 John moved to the University of Cambridge, where, funded through the Wellcome Trust’s Seeding Drug Discovery scheme, he led a number of protein-protein interaction inhibitor projects. In 2015 John moved within the University, to his present position as the CSO of the Alzheimer’s Research UK Cambridge Drug Discovery Institute.

Andrew Nichols
Andrew Nichols
CSO
Catabasis Pharmaceuticals
Andrew Nichols
CSO
Catabasis Pharmaceuticals

Andrew Nichols, Ph.D., is Chief Scientific Officer at Catabasis Pharmaceuticals, a rare disease-focused biotechnology company in Boston, MA. Andy is responsible for setting overall scientific strategy and leading all research, drug discovery, nonclinical and product development activities through a combination of in-house and external activities.

Jayanta Debnath
Jayanta Debnath
Distinguished Professor & Chair of Pathology
University of California San Francisco
Jayanta Debnath
Distinguished Professor & Chair of Pathology
University of California San Francisco

Jay Debnath is Distinguished Professor and Chair of Pathology at the University of California, San Francisco. His laboratory is widely recognized for its expertise on the diverse cell biological roles of autophagy during cancer progression and metastasis. Recently, he has been illuminating how the autophagy pathway orchestrates secretory and exocytic functions distinct from its long-recognized roles in catabolism.

Carles Domènech
Carles Domènech
Executive Chairman, CSO & Co-Founder
Ability Pharmaceuticals
Carles Domènech
Executive Chairman, CSO & Co-Founder
Ability Pharmaceuticals

Carles obtained a BSs/MSc degree in biology (first class honors) from the Autonomous University of Barcelona and also a PhD degree in cellular biology from the same University, working at the Council of Science Research (CSIC). He has additional business training at ESADE business school and other business programs.

After his career in CSIC in Barcelona (1985-89) and at Memorial Sloan-Kettering Cancer Center in New York (1990-1992), he held senior positions at  Almirall, SA (1992-2003) as Manager and Head of Business Development and Licensing and Lacer, SA (2005-2007) as Director, Business Development and Licensing.

Carles has also 4 years experience in biotech venture capital and business angels associations and has also been collaborating with government innovation agencies. Between 2004 and 2005 he was Director, Biotech Investments at the seed venture capital firm Barcelona Emprèn, SCRSA. During 2008-2009 he collaborated with agencies of the Government of Catalonia as Director, Technology Transfer and Valorization and as Managing Director, Investment and Enterprise Growth. He had under his responsibility the seed venture capital company Invertec, SA and the entrepreneurship finance programs Genesis Capital and Concept Capital. Since July 2009 he also advises Keiretsu Forum Barcelona in biotech investments.

In 2009 Carles cofounded Ability Pharmaceuticals, SL to become its Chief Executive Officer in September 2009

Christian Peters
Christian Peters
CEO
Pinpoint Therapeutics
Christian Peters
CEO
Pinpoint Therapeutics

Christian Peters, MD, PhD, is CEO and President of Pinpoint Therapeutics, Inc. and serves on its Board of Directors.  Christian has over 29 years’ experience, including 19 years of successful clinical development and commercialization in a number of senior leadership positions in the pharmaceutical industry, and more than 10 years of clinical and research experience in academic settings. Before this, Christian was the CMO for Realm Therapeutics and Therakos.

Prior to joining Therakos, Dr. Peters served at CSL Behring and its predecessor companies in multiple positions with increasing responsibilities in Clinical Development, Regulatory and Medical Affairs. At CSL Behring, Dr. Peters led or participated in teams that secured FDA approval for seven products.

Prior to his years in Industry, he was a National Research Service Award (NRSA) Fellow at the University of Pennsylvania, a Fogarty International Fellow at the National Institutes of Health (NIH), and a Resident at the University of Berlin in Germany after here earning his MD and PhD.

Christian Peters has been awarded NIH and other grants, has published in peer-reviewed journals, and holds five patents.

James Duce
James Duce
Head of Biology
ALBORADA Drug Discovery Institute
James Duce
Head of Biology
ALBORADA Drug Discovery Institute

James Duce obtained his Ph.D from Cardiff University in the neurobiology of Huntington’s disease. He broadened his neurodegenerative disease research knowledge through postdoctoral studies with Prof Carmela Abraham in Boston USA and Profs Colin Masters and Ashley Bush in Melbourne, Australia. His return to the UK in 2012, supported through an Alzheimer’s Research UK Senior Fellowship, enabled him to run a team at University of Leeds that validated several post-translational modifications as disease targets. He has subsequently led several internationally funded translational projects in neurodegenerative disease. James joined the ALBORADA Drug Discovery Institute as Head of Biology in 2017.

Vojo Deretic
Vojo Deretic
Director
Autophagy, Inflammation and Metabolism Center of Biomedical Research Excellence (AIM Center)
Vojo Deretic
Director
Autophagy, Inflammation and Metabolism Center of Biomedical Research Excellence (AIM Center)

Vojo Deretic, Ph.D., is the department chair of the Department of Molecular Genetics and Microbiology at the University of New Mexico School of Medicine and the director of the NIH-funded Autophagy, Inflammation and Metabolism (AIM) Center of Biomedical Research Excellence.  The AIM center aims to promote autophagy research nationally and internationally as well as to develop a cadre of junior faculty along with senior experts in this area to study fundamental mechanisms and how autophagy intersects with a broad spectrum of human disease and health states. Dr. Deretic received his undergraduate, graduate and postdoctoral education in Belgrade, Paris, and Chicago. His main contributions to science come from studies by his team on the role of autophagy in infection and immunity. Recently, his group has become interested in the specific connections between metabolic roles of autophagy and its quality control functions. 

Jorge Moscat
Jorge Moscat
Vice Chair for Experimental Pathology
Weill Cornell Medicine
Jorge Moscat
Vice Chair for Experimental Pathology
Weill Cornell Medicine
Rajat Singh
Rajat Singh
Associate Professor of Molecular Pharmacology and Medicine
Albert Einstein College of Medicine
Rajat Singh
Associate Professor of Molecular Pharmacology and Medicine
Albert Einstein College of Medicine

Agenda

  • Day 1 - Thursday, November 19th
  • Day 2 - Friday, November 20th
Day 1 - Thursday, November 19th
8:00 am
Registration, Breakfast & Networking
9:00 am
Chair’s Opening Remarks & Setting the Scene

Alec Kimmelman, Professor & Chair of the Department of Radiation Oncology | Founder & Scientific Consultant, NYU Langone Medical Center | Vescor Therapeutics

Deciphering the Fundamental Biology of Autophagy

9:10 am
Keynote Presentation - Drugging Autophagy: How far have we come and how far do we have to go?

Ravi Amaravadi, Associate Professor of Medicine | Co-Founder, University of Pennsylvania | Pinpoint Therapeutics

9:35 am
Panel - How Much is Our Understanding of the Fundamental Biology Impacting the Druggability of Autophagy?

Magdalene Moran, President & CSO, Caraway Therapeutics

Vojo Deretic, Director, Autophagy, Inflammation, and Metabolism Center of Biomedical Research Excellence (AIM Center)

Jorge Moscat, Vice-Chair for Experimental Pathology, Weill Cornell Medicine

10:20 am
Morning Refreshments & Networking

Autophagy Showcase: Crucial Case Studies

11:05 am
Presentation - Targeting TRPML1 for Neurodegenerative Disease

Magdalene Moran, President & CSO, Caraway Therapeutics

11:30 am
Presentation - Non-ATG Factors that Control Autophagy in Disease

Vojo Deretic, Director, Autophagy, Inflammation, and Metabolism Center of Biomedical Research Excellence (AIM Center)

11:55 am
Presentation - Enhancing Autophagy for the Treatment of Cystic Fibrosis

Andrew Nichols, CSO, Catabasis Pharmaceuticals

12:20
Presentation - Blocking Autophagy in RAS-Driven Cancers

Martin McMahon, Cumming-Presidential Chair of Cancer Biology/Senior Director for Preclinical Translation, University of Utah

12:45 pm
Lunch & Networking

Drug Discovery and Screening

2:05 pm
Presentation – Discovery of ULK1/2 Inhibitor DCC-3116 for Treatment of RAS-Driven Cancers

Daniel L. Flynn, Founder & CSO, Deciphera Pharmaceuticals, LLC

2:25 pm
Presentation - Targeting the Hallmarks of Aging

Jens Eckstein, Interim CEO, President & Director, Samsara Therapeutics

2:50 pm
Presentation - Autophagy Drug Discovery for Dementia

James Duce, Head of Biology, ALBORADA Drug Discovery Institute

3:15 pm
Afternoon Refreshments & Networking
3:50 pm
Presentation - Chemical Modulation of Chaperone-Mediated Autophagy

Evripidis Gavathiotis, Professor of Biochemistry and Medicine | Co-founder, Albert Einstein College of Medicine | Selphagy Therapeutics

4:15 pm
Strategically Focused Panel with Open Q&A - How Should We Drug Autophagy?

Andrew Nichols, Chief Scientific Officer, Catabasis Pharmaceuticals

Daniel L. Flynn, Founder & CSO, Deciphera Pharmaceuticals, LLC

Fiona Menzies, Research Advisor & Head of Proteostasis, Eli Lilly

Ravi Amaravadi, Associate Professor of Medicine | Co-Founder, University of Pennsylvania | Pinpoint Therapeutics

5:00 pm
Close of Day 1
Download Agenda
Day 2 - Friday, November 20th
8:00 am
Breakfast & Networking
9:00 am
Chair’s Opening Remarks

Andrew Thorburn, Professor & Chair, Department of Pharmacology, University of Colorado

Modeling Autophagy

9:10 am
Presentation - Understanding the Molecular Mechanisms of Immunosuppression by Autophagy

Aditya Murthy, Senior Scientist, Department of Cancer Immunology, Genentech

9:35 am
Presentation - Targeting Autophagy to Lower Blood Glucose in a Model of Diabetes

Rajat Singh, Associate Professor of Medicine and Molecular Pharmacology, Albert Einstein College of Medicine

10:15 am
Morning Refreshments & Networking

Autophagy in the Clinic

11:10 am
Presentation - Yin and Yang: Autophagy and the Secretory Pathways as a Biomarker

Jayanta (Jay) Debnath, Distinguished Professor & Chair of Pathology, University of California, San Francisco

11:35 am
Presentation - ABTL0812: A Novel Pro-Autophagic Drug in Phase 2 Clinical Trials

Carles Domènech, Executive Chairman, CSO & Co-Founder, Ability Pharmaceuticals

12:00 pm
Presentation to be Announced
12:25 pm
Panel and Open Q&A - How Close are We to Achieving an ‘Autophagy Signature’?

Jayanta (Jay) Debnath, Distinguished Professor & Chair of Pathology, University of California, San Francisco

1:05 pm
Lunch & Networking

Industry Leaders Discussion

2:15 pm
Panel and Open Q&A - What Do We Need to Achieve Next?

Moderated by: John Skidmore, CSO, Alzheimer’s Research UK Cambridge Drug Discovery Institute

Christian Peters, CEO, Pinpoint Therapeutics

Sean Smith, Executive Director of Neuroscience, Merck

Martin McMahon, Cumming-Presidential Chair of Cancer Biology/Senior Director for Preclinical Translation, University of Utah

2:55 pm
Chair’s Summary

Andrew Thorburn, Professor & Chair, Department of Pharmacology, University of Colorado

3:00 pm
Close of Drugging Autophagy 2020
Download Agenda

Partner with Us

The Drugging Autophagy Summit being online presents an opportunity for us to super-charge our offering. We have selected the best-in-class platform to offer our attendees a wide range of options to learn, network, and collaborate. The result, bringing together more senior R&D and business exec’s from across the industry.

Making your session engaging and knowledgeable will attract the largest audience.  We will guide you on how best to maximize the benefits of using our platform.

No need to sit behind a desk!  Our networking tools enable attendees to arrange 121 video conversations as well as taking part in curated networking sessions. You could potentially meet many more people than you would in a typical venue setting.

Get in touch to learn more about the options available.

Contact Us +
Partner with Us

Register for the Event

For pricing and booking options please click the button to go to the registration page.

Registration